Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss
暂无分享,去创建一个
K. Michaëlsson | L. Lind | J. Ärnlöv | J. Carrero | A. Larsson | J. Kullberg | H. Ahlström | U. Risérus | P. Stenvinkel | A. Witasp | V. Adamsson | J. Helmersson-Karlqvist
[1] G. Sinagra,et al. Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome , 2013, Cardiovascular Diabetology.
[2] R. Ajisaka,et al. Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals. , 2013, American journal of hypertension.
[3] J. Carrero,et al. Elevated Circulating Levels and Tissue Expression of Pentraxin 3 in Uremia: A Reflection of Endothelial Dysfunction , 2013, PloS one.
[4] W. Ryu,et al. Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. , 2012, Atherosclerosis.
[5] M. Shlipak,et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. , 2012, American heart journal.
[6] P. Cieślik,et al. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications , 2012, Autoimmunity.
[7] J. Moreno-Navarrete,et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. , 2011, American journal of physiology. Endocrinology and metabolism.
[8] J. Carrero,et al. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[9] G. Johansson,et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET) , 2011, Journal of internal medicine.
[10] T. Kodama,et al. Reciprocal Contribution of Pentraxin 3 and C‐Reactive Protein to Obesity and Metabolic Syndrome , 2010, Obesity.
[11] H. Sasai,et al. Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility? , 2010, Journal of atherosclerosis and thrombosis.
[12] H. Staines,et al. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain , 2009, Thrombosis and Haemostasis.
[13] G. Biolo,et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile , 2009, Clinical and Experimental Medicine.
[14] A. Mantovani,et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. , 2009, Atherosclerosis.
[15] T. Kodama,et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations , 2009, Clinical chemistry and laboratory medicine.
[16] C. Garlanda,et al. Pentraxins, humoral innate immunity and tissue injury. , 2008, Current opinion in immunology.
[17] Martina Heer,et al. Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. , 2008, The Journal of clinical endocrinology and metabolism.
[18] J. Carrero,et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[19] Philippe Pibarot,et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[20] J. Carrero,et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. , 2008, QJM : monthly journal of the Association of Physicians.
[21] C. Garlanda,et al. Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction , 2008, Circulation.
[22] J. Murabito,et al. Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: The Framingham Heart Study , 2007, Circulation.
[23] J. Carrero,et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[24] Udo Hoffmann,et al. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study , 2007, Circulation.
[25] L. Lönn,et al. Practical approach for estimation of subcutaneous and visceral adipose tissue , 2007, Clinical physiology and functional imaging.
[26] L. Hansson,et al. Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2 from the cystatin C values in mg/L , 2007, Scandinavian journal of clinical and laboratory investigation.
[27] Lars Lind,et al. A Comparison of Three Different Methods to Evaluate Endothelium-Dependent Vasodilation in the Elderly: The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[28] A. Larsson,et al. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. , 2005, Atherosclerosis.
[29] K. Wellen,et al. Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.
[30] C. Garlanda,et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.
[31] L. Hansson,et al. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L , 2004, Scandinavian journal of clinical and laboratory investigation.
[32] O. Bezy,et al. Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. , 2003, Journal of lipid research.
[33] A. Mantovani,et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q , 2003, European journal of immunology.
[34] S. Kritchevsky,et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. , 2003, Diabetes care.
[35] P. Scherer,et al. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism , 2002, Trends in Endocrinology & Metabolism.
[36] L. Reis,et al. TSG‐14 transgenic mice have improved survival to endotoxemia and to CLP‐induced sepsis , 2001, Journal of leukocyte biology.
[37] P. McKeigue,et al. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[38] B. Spiegelman,et al. AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.
[39] M. Rocchi,et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. , 1992, The Journal of biological chemistry.